Whereas hypermethylation of both FOXE1 and SYNE1 was absent among controls, promoter hypermethylation was detected in biopsies of 60% of patients with UC-CRC for FOXE1 and 80% for SYNE1. This evidence concerns the gene FOXE1 and colorectal carcinoma.